On June 25, Hims & Hers Health fell 5.32% in regular trading, trading at approximately $30.95/share, with turnover of $1.26 billion.

On the news front, the company recently filed a proposed securities sale announcement and disclosed a shareholding change statement on June 24, with potential share reduction signals continuing to weigh on sentiment. The stock had rallied from approximately $28.91 to $35.47 over the prior week, accumulating gains exceeding 22%, intensifying profit-taking pressure.

The broader context adds further weight: in its Q1 earnings reported in May, the company swung to a net loss of $92 million versus $50 million a year earlier, as costs related to restructuring its GLP-1 product line — including approximately $33 million in supply chain write-downs — pressured margins. While the company's pivot to FDA-approved GLP-1 drugs drove record platform traffic and app downloads, near-term profitability remains under pressure from strategic investments in supply chain integration and international expansion.

Hims & Hers Health, Inc. operates a telehealth consultation platform connecting consumers to healthcare professionals for mental health, sexual health, dermatology, and primary care services. The company was founded in 2017 and is headquartered in San Francisco, CA.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)